Background: Hidradenitis suppurativa (HS) is a chronic skin disorder with adverse impacts on both physical and psychosocial well-being. There is presently no validated HS-specific quality-of-life (QoL) measure. Objective: The objective of this study is to develop a QoL instrument for HS (HS-QoL) in accordance with recommended standards. Methods: Patient interviews (concept elicitation) and expert input were used to develop the conceptual framework for outcomes perceived important to patients with HS. A HS-QoL-v1 measure was developed, and cognitive interviews with patients were conducted for pilot testing. Results: Concept elicitation interviews with patients with HS (n = 21) generated 12 themes. Most frequently reported were impacts on daily activities and symptoms due to HS. These themes, along with literature review and input from clinical experts, informed development of the HS-QoL-v1. Nine cognitive interviews were conducted in a pilot test and resulted in the HS-QoL-v2 measure.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease manifested by deep-seated nodules and cysts typically in intertriginous sites, including axillae, breasts, groin, buttocks, and perineum. HS has been associated with significant impacts on physical and psychological well-being due to pain, embarrassment, and isolation [1] [2] [3] [4] and deemed to be amongst the most distressing of skin conditions. 5 Despite this, there is paucity of progress in understanding the impact of HS-establishing it as a top research priority for this disease. 6 As HS is a chronic condition and remissions difficult to achieve, improvements in quality of life (QoL) should be an important goal of treatment. A disease-specific QoL for HS is critical due to the unique nature of HS lesions and their location, which merits a measure inclusive of unique physical, social, and emotional domains. 7, 8 The HS priority-setting partnership data also identified uncertainties in multiple therapy areas in which randomised controlled trial data are sparse. 6 Recent European guidelines recommend several medical therapies for HS, including topical antiseptics, oral tetracyclines, and oral disease modifiers, followed by antitumour necrosis factor α therapies for severe disease, in parallel with local or wider surgical techniques. 9 Given the upsurge of interest in HS, a disease-specific QoL would facilitate future research by serving as a patient-centric measure of improvement, independent of clinician-reported outcomes such as inflammatory lesion counts. 10 Accordingly, the objective of this study is to develop a QoL for HS (HS-QoL) adherent to recommended standards of development.
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Methods
The methods used herein were in accordance with guidance from the US Food and Drug Administration and the National Institutes of Health for development of patient-reported outcomes (PROs) based on modern measurement theory. content validity. See Figure 1 for steps in developing the measure.
Phase I: Concept Elicitation Interviews (HS-QoL-v1)
Participants in this phase were recruited from a search of the electronic medical record (January 1, 2012, through (Table 1a) , which allowed for topic consistency and flexibility. All interviews were tape-recorded and transcribed verbatim. These transcripts were subsequently reviewed line by line, and words, phrases, and passages related to the impacts (restrictions, symptoms, and outcomes) of HS were coded using thematic analysis (M.S.).
Themes were selected if saturation had been reached in the concept elicitation interviews and were used to generate items for the HS-QoL-v1. Items from other QoL measures used in previous HS studies were extracted and those items deemed relevant (by 3 research associates: M.S., S.B., and L.P.) were also included in the preliminary measure. Two dermatologists (J.S.K. and J.T.) examined the measure to ensure that clinically relevant aspects of each concept were captured.
Phase 2: Pilot Test With Cognitive Interviews (HS-QoL-v2)
Participants in this phase were identified from an electronic database of medical records (March-May 2016) of a dermatology practice in Windsor, Ontario, Canada (office of J.T.). Patients who had a diagnosis of HS and indicated interest in participating were contacted by phone and asked to participate in a 30-minute interview. Patients received a $30 stipend for participation. This protocol was approved by the Applied Social Psychology Training Research Ethics Committee at the University of Windsor.
Upon agreeing to participate, an interview was scheduled and all participants were emailed a letter of information, the preliminary measure, and questions to be asked during the interview. Participants were asked to be prepared to discuss their views on whether the questions/ answers accurately and appropriately reflected their experience with HS. After reviewing and signing the consent form, the interviews commenced. The interviewer (C.M.) followed a structured guide to ensure that all participants received the same questions (Table 1b ). All the interviews were audio-recorded and transcribed. Transcripts were analysed using thematic analysis and the measure was refined to produce the HS-QoL-v2. Patients described 12 major themes/concepts (see Table 2 ): (1) impacts on daily activities, (2) symptoms due to HS, (3) emotional consequences, (4) psychosocial consequences, (5) restricted clothing choices, (6) coping, (7) sexual functioning, (8) work/economic consequences, (9) interactions with medical personnel, (10) social support, (11) symptoms due to treatment, and (12) concentration issues at work and/or leisure activities. Concepts from the literature review and concept elicitation interviews were used to generate measure items (HS-QoL-v1). Participants indicated that the HS-QoL-v1 was thorough, brought awareness to a condition that is understudied, and asked about relevant issues and symptoms. Five main concerns/themes arose from the cognitive interviews (see Table 3 ): (1) lack of knowledge of health professionals to diagnose HS, (2) concern regarding the reference point (time frame) for questions, (3) 1 unclear item, (4) 3 items considered irrelevant, and (5) 2 themes identified as missing. In addition, most participants (n = 7 [77.8%]) indicated that they considered both scars and active lesions while reviewing the questionnaire. Response saturation was achieved with 9 participants.
Results
Phase 1: Concept Elicitation Interviews
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The HS-QoL-v1 was modified based on these findings: 4 items were removed, 1 altered to improve clarity, and 2 added to reflect patient concerns about difficulties encountered while seeking diagnosis. Text was also modified to differentiate active inflammatory lesions of HS from secondary lesions such as scars and tracts. The resulting HS-QoL-v2 consisted of 53 items. Participants responded to items using a 5-point Likert scale, where 1 = not at all and 5 = extremely. In the latter sections of the scale, participants respond using 5-point Likert scale, where 1 = never and 5 = all the time. Higher scores indicate a greater degree of impact on quality of life.
Discussion
This study is largely consistent with findings of other qualitative and quantitative studies on HS, which showed adverse impacts on emotions, intimate relations, stigmatisation, precautions, and occupation. 7, 13 Previous studies on HS have not comprehensively addressed the impact of this condition, including the physical, social, and psychological domains. 7, 10 HS has previously been neglected in medical research, and there is current uncertainty regarding optimal management. While this study found similar adverse effects of HS on QoL as in other studies, new dimensions were discovered. Concrete themes of coping and positive impacts of social support added dimensions of potential strengths. Researchers often examine individuals' deficits (eg, negative impacts on their lives) rather than, or in combination with, the strengths individuals have or acquire as part of living with their condition. The measure developed in this study addresses QoL in a comprehensive manner, including both negative and positive aspects. Existing studies in HS have used 3 categories of QoL measures: skin specific, general health, and psychosocial well-being. 7, [14] [15] [16] [17] General QoL measures (unrelated to skin or HS) have some value as they allow for the impacts of conditions to be similarly compared. 2 However, people with HS have a multifaceted experience that cannot be accurately measured by a questionnaire that only enquires about general health-related QoL. Only 1 study of fistulizing HS included a modified measure with HS-specific QoL items, 18 although that measure has not been validated.
The HS-QoL-v2 developed in this study is a 53-item questionnaire suitable for use in patients with HS. Based on literature review, concept elicitation interviews, item generation, and cognitive interviews, the HS-QoL-v2 has demonstrated content validity. This version is currently undergoing psychometric validation and will subsequently require clinimetric evaluation for reliability, discriminant capacity, and responsiveness.
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